Jupiter Topco LLC purchased a new stake in shares of Harrow, Inc. (NASDAQ:HROW – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 579,127 shares of the company’s stock, valued at approximately $24,596,000.
Several other institutional investors and hedge funds also recently made changes to their positions in HROW. Royal Bank of Canada lifted its position in Harrow by 102.5% in the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after acquiring an additional 4,967 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares in the last quarter. Strs Ohio bought a new stake in shares of Harrow in the 1st quarter worth $149,000. Legal & General Group Plc raised its stake in shares of Harrow by 12.4% in the second quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock worth $939,000 after purchasing an additional 3,384 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Harrow by 9.3% in the second quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock worth $1,434,000 after purchasing an additional 3,994 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.
Harrow Price Performance
NASDAQ HROW opened at $37.27 on Friday. The business’s fifty day moving average price is $41.28 and its 200-day moving average price is $39.57. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -37.27 and a beta of 0.28. The company has a debt-to-equity ratio of 19.70, a current ratio of 2.24 and a quick ratio of 2.08. Harrow, Inc. has a 1-year low of $28.54 and a 1-year high of $54.85.
Analyst Ratings Changes
HROW has been the topic of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research report on Monday, July 20th. Cantor Fitzgerald lowered their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Harrow presently has a consensus rating of “Moderate Buy” and an average price target of $69.43.
Check Out Our Latest Research Report on HROW
Insider Transactions at Harrow
In other Harrow news, insider Amir Shojaei sold 11,250 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $40.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 11,250 shares of the company’s stock, valued at approximately $450,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 12.80% of the company’s stock.
About Harrow
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
Featured Stories
- Five stocks we like better than Harrow
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW – Free Report).
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
